abstract |
The invention relates to the use of compounds of the formula (see formula (I)) in which R 1 is hydrogen, deuterium, tritium, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, or is phenyloxy, benzyl, benzyloxy, -COO-lower alkyl, -O- (CH2) or O-lower alkyl, NH-cycloalkyl, cycloalkyl or tetrahydropyran-4-yloxy, the substituents for n> 1 may be same or different; X is a link, -CHR-, -CHRCHR´-, -OCH2-, -CH2OCHR-, -CH2CH2CH2-, -SCH2-, -S (O) 2CH2-, -CH2SCH2-, -CH2N (R) CH2- - cycloalkyl-CH2- or SiRR´-CH2-; R / R 'independently of one another may be hydrogen, lower alkyl or lower alkyl substituted by halogen; R2 is hydrogen, phenyl or lower alkyl; Y is phenyl, naphthyl, thiophenyl, pyridinyl, cycloalkyl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 2,3-dihydrobenzo [1,4] dioxin-6-yl or benzo [1,3] dioxol-5-yl; n is the number 0, 1, 2 or 3; or is the number 2 or 3; or to a pharmaceutically acceptable acid addition salt for the manufacture of medicaments for the treatment of diseases related to the biological function of receptors associated with trace amines, the diseases are: depression, anxiety disorders, bipolar disorder, disorder of attention deficit hyperactivity, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature, homeostasis, sleep disorders and circadian rhythm and cardiovascular disorders. |